BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38475919)

  • 1. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
    Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
    Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
    Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
    Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
    Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
    Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
    Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
    Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene.
    Odaira K; Yasuda T; Okada K; Shimooka T; Kojima Y; Noura M; Tamura S; Kurahashi S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
    Cancer Sci; 2023 Mar; 114(3):781-792. PubMed ID: 36341510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
    Katzerke C; Madan V; Gerloff D; Bräuer-Hartmann D; Hartmann JU; Wurm AA; Müller-Tidow C; Schnittger S; Tenen DG; Niederwieser D; Behre G
    Blood; 2013 Oct; 122(14):2433-42. PubMed ID: 23974200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.
    Pal P; Lochab S; Kanaujiya JK; Kapoor I; Sanyal S; Behre G; Trivedi AK
    Cell Death Dis; 2013 Apr; 4(4):e590. PubMed ID: 23598402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
    Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
    Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A C/ebpα isoform specific differentiation program in immortalized myelocytes.
    Garcia-Cuellar MP; Akan S; Slany RK
    Leukemia; 2023 Sep; 37(9):1850-1859. PubMed ID: 37532789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
    Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
    Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
    O'Connor C; Lohan F; Campos J; Ohlsson E; Salomè M; Forde C; Artschwager R; Liskamp RM; Cahill MR; Kiely PA; Porse B; Keeshan K
    Oncogene; 2016 Oct; 35(40):5272-5281. PubMed ID: 26996668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
    Schmidt L; Heyes E; Grebien F
    Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
    Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
    Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation.
    Wang D; Sun T; Xia Y; Zhao Z; Sheng X; Li S; Ma Y; Li M; Su X; Zhang F; Li P; Ma D; Ye J; Lu F; Ji C
    Nat Commun; 2023 Oct; 14(1):6907. PubMed ID: 37903757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
    Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
    Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.